Merck KGaA / MilliporeSigma (CDMO) vs Pfizer CentreOne: CDMO Comparison
How does Merck KGaA / MilliporeSigma (CDMO) compare to Pfizer CentreOne for mRNA/LNP manufacturing?
Side-by-side comparison of Merck KGaA / MilliporeSigma (CDMO) and Pfizer CentreOne on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Pfizer CentreOne has materially broader EMA GMP coverage (14 active certificates vs 2) — stronger EU footprint.
- Pfizer CentreOne maintains 3 MHRA / UK GMP certificates; Merck KGaA / MilliporeSigma (CDMO) does not.
- Pfizer CentreOne appears as a manufacturing partner on more matched clinical programs (366 vs 22) — a broader sponsor book.
On a 13-modality CDMO landscape, both Merck KGaA / MilliporeSigma (CDMO) and Pfizer CentreOne qualify as mRNA/LNP manufacturers; Pfizer CentreOne carries the higher composite Signal Score for mRNA/LNP programs in this comparison.
What to evaluate for mRNA/LNP programs
Both Merck KGaA / MilliporeSigma (CDMO) and Pfizer CentreOne qualify as mRNA/LNP CDMOs. When choosing between them for mRNA/LNP programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.
Frequently asked: Merck KGaA / MilliporeSigma (CDMO) vs Pfizer CentreOne
How does Merck KGaA / MilliporeSigma (CDMO) compare to Pfizer CentreOne for mRNA/LNP manufacturing?
On CDMO Signal's composite Signal Score, Merck KGaA / MilliporeSigma (CDMO) is 82/100 and Pfizer CentreOne is 92/100; Merck KGaA / MilliporeSigma (CDMO) has 2 FDA inspections on record vs 4 for Pfizer CentreOne; European coverage is 2 active EMA+MHRA certificates for Merck KGaA / MilliporeSigma (CDMO) vs 17 for Pfizer CentreOne. Both are tracked in the CDMO Signal directory as mRNA/LNP CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Merck KGaA / MilliporeSigma (CDMO) or Pfizer CentreOne?
Both Merck KGaA / MilliporeSigma (CDMO) and Pfizer CentreOne maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Merck KGaA / MilliporeSigma (CDMO) has 2 FDA inspections on record; Pfizer CentreOne has 4.
How do Merck KGaA / MilliporeSigma (CDMO) and Pfizer CentreOne compare on European GMP coverage?
Merck KGaA / MilliporeSigma (CDMO) holds 2 active EMA GMP certificates and 0 MHRA / UK certificates. Pfizer CentreOne holds 14 active EMA GMP certificates and 3 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Merck KGaA / MilliporeSigma (CDMO) or Pfizer CentreOne?
Merck KGaA / MilliporeSigma (CDMO) is matched to 22 ClinicalTrials.gov records as a manufacturing partner; Pfizer CentreOne is matched to 366. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for mRNA/LNP manufacturing — Merck KGaA / MilliporeSigma (CDMO) or Pfizer CentreOne?
Both Merck KGaA / MilliporeSigma (CDMO) and Pfizer CentreOne are tagged as mRNA/LNP CDMOs in our directory, so both are credible options for mRNA/LNP programs. The most important differentiator for mRNA/LNP selection is typically ivt mrna synthesis: Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →